Skip to main content

Table 5 Rates of antimicrobial susceptibility for the common gram-negative organisms identified

From: Bloodstream infections at a tertiary level paediatric hospital in South Africa

  Acinetobacter baumanii (N = 59) Escherichia coli (N = 92) Klebsiella pneumoniae (N = 92) Pseudomonas aeruginosa (N = 26) Non-typhoidal Salmonella (N = 20)
Antimicrobial No isolates tested No (%) Susceptible No isolates tested No (%) Susceptible No isolates tested N (%) Susceptible No isolates tested N (%) Susceptible No isolates tested N (%) Susceptible
Ampicillin 91 9 (9.9) 92 20 19 (95)
Co-amoxyclava 89 43 (48.3) 91 27 (29.7) 1 1 (100)
Ceftriaxone 90 59 (65.6) 88 20 (22.7) 20 20 (100)
Ceftazidime 59 24 (40.7) 91 60 (65.9) 91 20 (22) 26 23 (88.5) 1 1 (100)
Ciprofloxacin 59 45 (76.3) 87 70 (80.5) 85 52 (61.2) 26 15 (57.7) 19 18 (94.7)
Piperacillin-tazobactam 58 10 (17.2) 6$ 5 (83.3) 49$ 34 (69.4) 7$ 1 (14.3) 1$ 1 (100)
Gentamicin 59 27 (45.8) 91 64 (70.3) 89 25 (28.1) 25 15 (60)
Amikacin 58 26 (44.8) 92 77 (83.7) 91 70 (76.9) 26 16 (61.5)
Meropenem 56 26 (46.4) 92 92 (100) 92 92 (100) 26 22 (84.6) 20 20 (100)
Imipenem 49 27 (55.1) 90 90 (100) 90 90 (100) 26 21 (80.8) 20 20 (100)
Ertapenem    92 92 (100) 91 91 (100) 20 20 (100)
Colistin 59 59 (100) 90 90 (100) 89 89 (100) 26 23 (88.5)
  1. aCo-amoxyclav = Amoxycillin-clavulanic acid co-formulation $ due to technical limitations with the Vitek®2 AST card piperacillin-tazobactam was infrequently reported in 2011–2012; No number